PETALING JAYA: Drug prices are more likely to increase from the weak ringgit than the Trans-Pacific Partnership Agreement (TPPA), according to the Malaysian Organisation of Pharmaceutical Industries (Mopi).
“The overall impact on the price of medicines is more heavily affected by the movement of our forex (foreign exchange) and the current economic challenges that we are facing now,” said the organisation’s president Diong Sing Peng.
